MINERALYS THERAPEUTICS, INC. COMMON STOCK
NASDAQ: MLYS (Mineralys Therapeutics, Inc.)
Kemas kini terakhir: 2 jam lalu15.52
-0.29 (-1.83%)
| Penutupan Terdahulu | 15.81 |
| Jumlah Dagangan | 1,718,414 |
| Harga / Buku (P/B) | 2.78 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -3.75 |
| Nisbah Semasa (MRQ) | 26.48 |
| Aliran Tunai Operasi (OCF TTM) | -192.66 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -122.17 M |
| Pulangan Atas Aset (ROA TTM) | -35.87% |
| Pulangan Atas Ekuiti (ROE TTM) | -56.31% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Mineralys Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Nilai 35% | -1.7 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | -1.7 |
| Masa 35% | -2.5 |
| AI Technical info | NA |
| Osilator Teknikal info | -2.5 |
| Purata Bergerak Teknikal info | -2.5 |
| Wang Pintar 30% | 0.0 |
| Konsensus Penganalisis info | 0.0 |
| Aktiviti Orang Dalam info | NA |
| Persekitaran | ×1.21 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -22.5% |
| Persetujuan Tonggak | ×1.25 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | 3.7 |
| Skor Akhir | -2.23 |
|
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.40% |
| % Dimiliki oleh Institusi | 103.83% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Catalys Pacific, Llc | 30 Sep 2026 | 7,799,518 |
| Ra Capital Management, L.P. | 30 Jun 2026 | 7,692,750 |
| Samsara Biocapital, Llc | 30 Jun 2026 | 5,871,018 |
| Deerfield Management Company, L.P. | 30 Jun 2026 | 3,958,000 |
| Laurion Capital Management Lp | 30 Sep 2026 | 2,481,698 |
| Orbimed Advisors Llc | 30 Jun 2026 | 2,110,300 |
| Capital World Investors | 30 Jun 2026 | 1,997,607 |
| Armistice Capital, Llc | 30 Jun 2026 | 1,736,000 |
| Troluce Capital Advisors Llc | 30 Jun 2026 | 1,728,753 |
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |